CN105595346A - 一种用于补钙的液体制剂及其制备方法 - Google Patents
一种用于补钙的液体制剂及其制备方法 Download PDFInfo
- Publication number
- CN105595346A CN105595346A CN201510547249.9A CN201510547249A CN105595346A CN 105595346 A CN105595346 A CN 105595346A CN 201510547249 A CN201510547249 A CN 201510547249A CN 105595346 A CN105595346 A CN 105595346A
- Authority
- CN
- China
- Prior art keywords
- calcium
- preparation
- liquid preparation
- replenishing
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011575 calcium Substances 0.000 title claims abstract description 109
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 95
- 238000002360 preparation method Methods 0.000 title claims abstract description 94
- 239000007788 liquid Substances 0.000 title claims abstract description 82
- 230000009469 supplementation Effects 0.000 title abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 24
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims abstract description 16
- 108010011485 Aspartame Proteins 0.000 claims abstract description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229920001100 Polydextrose Polymers 0.000 claims abstract description 8
- 239000000605 aspartame Substances 0.000 claims abstract description 8
- 235000010357 aspartame Nutrition 0.000 claims abstract description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 8
- 229960003438 aspartame Drugs 0.000 claims abstract description 8
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 8
- 239000001259 polydextrose Substances 0.000 claims abstract description 8
- 229940035035 polydextrose Drugs 0.000 claims abstract description 8
- 235000013856 polydextrose Nutrition 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 39
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 37
- 230000001954 sterilising effect Effects 0.000 claims description 26
- 239000004471 Glycine Substances 0.000 claims description 19
- 238000007689 inspection Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 12
- 235000013361 beverage Nutrition 0.000 claims description 9
- 239000011259 mixed solution Substances 0.000 claims description 8
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 7
- 239000001639 calcium acetate Substances 0.000 claims description 7
- 235000011092 calcium acetate Nutrition 0.000 claims description 7
- 229960005147 calcium acetate Drugs 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 229940098462 oral drops Drugs 0.000 claims description 7
- 238000004806 packaging method and process Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- 238000010792 warming Methods 0.000 claims description 7
- 230000000295 complement effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 238000005538 encapsulation Methods 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 9
- 230000036541 health Effects 0.000 abstract description 8
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 abstract description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 7
- 235000010241 potassium sorbate Nutrition 0.000 abstract description 7
- 239000004302 potassium sorbate Substances 0.000 abstract description 7
- 229940069338 potassium sorbate Drugs 0.000 abstract description 7
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract description 7
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract description 7
- 208000019505 Deglutition disease Diseases 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- OFNJDDJDXNMTHZ-UHFFFAOYSA-L calcium;2-aminoacetate Chemical compound [Ca+2].NCC([O-])=O.NCC([O-])=O OFNJDDJDXNMTHZ-UHFFFAOYSA-L 0.000 abstract 2
- 239000004386 Erythritol Substances 0.000 abstract 1
- 235000019414 erythritol Nutrition 0.000 abstract 1
- 229940009714 erythritol Drugs 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 80
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 36
- 229910000019 calcium carbonate Inorganic materials 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000002253 acid Substances 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 9
- 230000037396 body weight Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000037182 bone density Effects 0.000 description 4
- 230000001079 digestive effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- 206010006956 Calcium deficiency Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 230000003913 calcium metabolism Effects 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002133 sample digestion Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010034156 Pathological fracture Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 description 1
- -1 calisanin Chemical compound 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- XQRLCLUYWUNEEH-UHFFFAOYSA-L diphosphonate(2-) Chemical compound [O-]P(=O)OP([O-])=O XQRLCLUYWUNEEH-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004900 laundering Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000007442 rickets Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
剂量组 | 动物数(只) | 始重(g) | 终重(g) | 增重(g) |
实施例1 | 10 | 71.5±2.0 | 505.8±34.1 | 434.3±36.2 |
实施例2 | 10 | 73.5±3.0 | 515.1±32.2 | 441.6±40.7 |
实施例3 | 10 | 70.8±3.2 | 517.1±30.8 | 446.3±35.8 |
实施例4 | 10 | 71.4±2.8 | 514.1±32.5 | 442.7±29.5 |
实施例5 | 10 | 73.4±2.1 | 504.3±33.2 | 430.9±27.4 |
基础饲料组 | 10 | 71.6±3.0 | 441.1±32.4 | 369.5±31.2 |
碳酸钙对照组 | 10 | 72.5±2.8 | 475.7±33.8 | 403.2±33.7 |
剂量组 | 动物数(只) | 摄入钙(mg/d) | 粪钙(mg/d) | 表现吸收率 |
实施例1 | 10 | 220.7±17.5 | 60.4±9.5 | 73.5±7.27 --> |
实施例2 | 10 | 215.8±18.8 | 30.8±10.9 | 78.8±5.8 |
实施例3 | 10 | 221.7±15.4 | 44.6±13.7 | 80.5±3.2 |
实施例4 | 10 | 216.4±19.7 | 47.8±12.1 | 77.7±6.1 |
实施例5 | 10 | 218.7±14.5 | 56.2±18.3 | 74.5±8.5 |
基础饲料组 | 10 | 78.4±8.3 | 24.5±17.0 | 70.2±4.8 |
碳酸钙对照组 | 10 | 209.7±19.5 | 48.8±15.4 | 62.4±8.5 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547249.9A CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510547249.9A CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105595346A true CN105595346A (zh) | 2016-05-25 |
CN105595346B CN105595346B (zh) | 2018-12-11 |
Family
ID=55976149
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510547249.9A Active CN105595346B (zh) | 2015-09-01 | 2015-09-01 | 一种用于补钙的液体制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105595346B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107411096A (zh) * | 2017-05-17 | 2017-12-01 | 悦康动力(北京)科技有限公司 | 一种高钙含量液态补钙制剂及其制备方法 |
CN112370467A (zh) * | 2019-11-05 | 2021-02-19 | 广州富诺营养科技有限公司 | 一种含有铁、锌、钙的滴剂及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032037A1 (en) * | 1999-11-01 | 2001-05-10 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
CN101531609A (zh) * | 2009-04-15 | 2009-09-16 | 无锡市祖平食品科技有限公司 | 一种甘氨酸钙的制备方法 |
JP2010126431A (ja) * | 2008-12-01 | 2010-06-10 | Fukuei Hiryo Kk | アミノ酸キレートカルシウム含有液体肥料 |
CN102526009A (zh) * | 2012-02-21 | 2012-07-04 | 常熟市方塔涂料化工有限公司 | 一种葡萄糖酸钙锌口服溶液 |
CN103690559A (zh) * | 2014-01-05 | 2014-04-02 | 刘春华 | 补充剂钙镁铁锌的制剂类型及其中口服液制备方法 |
CN104489701A (zh) * | 2014-12-10 | 2015-04-08 | 常州兆阳光能科技有限公司 | 补钙保健营养液 |
-
2015
- 2015-09-01 CN CN201510547249.9A patent/CN105595346B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001032037A1 (en) * | 1999-11-01 | 2001-05-10 | Albion International, Inc. | Compositions and methods for calcium fortification of dairy products and oleaginous foods |
JP2010126431A (ja) * | 2008-12-01 | 2010-06-10 | Fukuei Hiryo Kk | アミノ酸キレートカルシウム含有液体肥料 |
CN101531609A (zh) * | 2009-04-15 | 2009-09-16 | 无锡市祖平食品科技有限公司 | 一种甘氨酸钙的制备方法 |
CN102526009A (zh) * | 2012-02-21 | 2012-07-04 | 常熟市方塔涂料化工有限公司 | 一种葡萄糖酸钙锌口服溶液 |
CN103690559A (zh) * | 2014-01-05 | 2014-04-02 | 刘春华 | 补充剂钙镁铁锌的制剂类型及其中口服液制备方法 |
CN104489701A (zh) * | 2014-12-10 | 2015-04-08 | 常州兆阳光能科技有限公司 | 补钙保健营养液 |
Non-Patent Citations (2)
Title |
---|
杨月欣等: "《营养功能成分应用指南》", 30 June 2011, 北京大学医学出版社 * |
蒋金来等: "钙制剂研究进展", 《食品工业科技》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107411096A (zh) * | 2017-05-17 | 2017-12-01 | 悦康动力(北京)科技有限公司 | 一种高钙含量液态补钙制剂及其制备方法 |
CN112370467A (zh) * | 2019-11-05 | 2021-02-19 | 广州富诺营养科技有限公司 | 一种含有铁、锌、钙的滴剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN105595346B (zh) | 2018-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103083648B (zh) | 以乳矿物盐为原料的增加骨密度的片剂及其制备方法 | |
CN103251671A (zh) | 一种增加骨密度的含中药的组合物及其制备方法 | |
CN104705658A (zh) | 一种具有增加骨密度功能的保健食品 | |
CN107581255A (zh) | 一种改善睡眠质量的组合物及其制备方法 | |
CN106723021A (zh) | 一种改善睡眠的功能性食品 | |
CN109700011A (zh) | 一种改善睡眠的保健食品及其制备方法 | |
CN102805858A (zh) | 一种高效补钙胶囊及制备方法 | |
CN108497498A (zh) | 一种解酒护肝的功能性食品及其制备方法 | |
CN103584106A (zh) | 一种具有增加骨密度功能的组合物 | |
CN105595346B (zh) | 一种用于补钙的液体制剂及其制备方法 | |
CN107319232A (zh) | 含钙饮剂及其制备方法 | |
CN107417556A (zh) | L‑天门冬氨酸螯合钙及其制备方法 | |
CN105055855B (zh) | 具有改善睡眠、增强免疫力作用的中药组合物及其制备方法和应用 | |
CN102302137A (zh) | 一种改善睡眠的保健食品 | |
CN103349674B (zh) | 一种增加骨密度、防治骨质疏松症的龟甲林蛙油组合物 | |
CN101690589B (zh) | 一种增加骨密度的保健品及其制备方法 | |
CN105410941A (zh) | 能增加骨密度和免疫力的祺然片保健食品及其制法 | |
CN108968075A (zh) | 一种提高骨骼健康的组合物及其应用 | |
CN104256576B (zh) | 一种调理血压平衡的功能性食品 | |
CN107308317A (zh) | 一种防治辐射损伤的中药组合物及辐射损伤动物模型的构建方法 | |
CN102028138A (zh) | 一种用于通便的组合物及其制备方法 | |
CN102626420B (zh) | 一种含有锶、钙和维生素d的混合制剂 | |
CN102475201A (zh) | 一种具有保健功能的蛋白粉组合物 | |
CN105476953B (zh) | 一种用于补铁的液体制剂及其制备方法 | |
CN107243013A (zh) | 一种改善骨密度的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Zhang Wei Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Zhang Wei Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190114 Address after: 102446 110m of Xiaoying Village Committee, Liangxiang Township, Fangshan District, Beijing Patentee after: Congrui Huikang (Beijing) Technology Development Co., Ltd. Address before: Room 302, Building 1, Gongxing Garden, Liangxiang, Fangshan District, Beijing Patentee before: Zhang Wei |
|
TR01 | Transfer of patent right |